Australasian Viral Hepatitis Elimination Conference 2017

The inaugural Australasian Viral Hepatitis Elimination Conference 2017, taking place at the Pullman Cairns International, Queensland, 10–11 August 2017, aims to gather those working in the field of Viral Hepatitis – as well as policy makers, researchers, primary health care providers and other individuals committed towards virtual hepatitis elimination. The program will present the latest […]

Hepatitis B Vaccine Shortage

Hepatitis ACT understands from pharmaceutical company GlaxoSmithKline (GSK) that there is a national shortage of the adult dose of the hepatitis B vaccine, and as a result they say “GSK prioritises hepatitis B vaccine availability for those most at risk of infection and confirms uninterrupted supply of Engerix-B to all Australian State, Territory and Federal […]

Safety advisory – risk of hepatitis B virus reactivation

19 December 2016 Consumers and Healthcare Professionals are advised that direct-acting antiviral (DAA) medicines for the treatment of chronic hepatitis C virus (HCV) infection have been associated with reactivation of hepatitis B virus (HBV) in patients with a current or previous HBV infection. A recent TGA review of the available data, including data from international […]

World Hepatitis Day 2016: Acknowledging achievements and progress

World Hepatitis Day Observed each year on 28 July, World Hepatitis Day is an international event focused on raising awareness about viral hepatitis and influencing real change in disease prevention and access to testing and treatment. It is coordinated globally by the World Hepatitis Alliance, and driven nationally by Hepatitis Australia and its state/territory member […]